| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/15/2005 | US20050203104 Cycloalkyl - containing 5-acylindolinones, the preparation thereof and their use as medicaments |
| 09/15/2005 | US20050203103 Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them |
| 09/15/2005 | US20050203102 Oxazolidinone derivatives such as (S)-N-[3-[3-fluoro-4-[4-[4-[(3-carboxymethyl-5-oxo-2-thioxo-1,3-thiazolidin-3-yl)methine]phenyl]piperazin-1 -yl]phenyl]-2-oxooxazolidin-5-ylmethyl] acetamide; antibiotics; use against Vancomycin resistant organisms, methicillin resistant organisms |
| 09/15/2005 | US20050203101 Benzimidazole quinolinones and uses thereof |
| 09/15/2005 | US20050203100 Administering acridin-9-yl-[4-(4-methylpiperazin-1-yl)-phenyl]amine (JP-1302); cognition activators, drug abuse, alcoholism, cigarette smoking cessation, schizophrenia, Tourette*s syndrome, epilepsy, psychosis; sexual, psychological, obsessive-compulsive, or nervous system disorders; psychiatry |
| 09/15/2005 | US20050203099 Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof |
| 09/15/2005 | US20050203098 Use of tyrosine kinase inhibitors for treating substance use disorders |
| 09/15/2005 | US20050203097 Pharmaceutical composition comprising pimobendan |
| 09/15/2005 | US20050203095 Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions |
| 09/15/2005 | US20050203094 Thromboembolic disorders; anticoagulants; e.g. 2-[5'-fluoro-2,2'-dihydroxy-5-(2-oxo-tetrahydro-furan-3-yl)-biphenyl-3-yl]-1H-benzoimidazole-5-carboxamidine |
| 09/15/2005 | US20050203093 Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 09/15/2005 | US20050203091 Heteroaryl-fused pyrazolo derivatives and methods for using the same |
| 09/15/2005 | US20050203090 Methods of using N-alkyl-hydroxamic acid-isoindolyl compounds |
| 09/15/2005 | US20050203089 N-substituted prodrugs of fluorooxindoles |
| 09/15/2005 | US20050203088 Medicament combinations based on scopine- or tropene acid esters with EGFR-kinase inhibitors |
| 09/15/2005 | US20050203087 Inhibitors of protein tyrosine phosphatase 1B |
| 09/15/2005 | US20050203086 Methods of treatment using an EP2 selective receptor agonist |
| 09/15/2005 | US20050203085 Rifamycin C-11 oxime cyclo derivatives effective against drug-resistant microbes |
| 09/15/2005 | US20050203084 Protease inhibitors |
| 09/15/2005 | US20050203083 Bronchodilators; treating chronic obstructive pulmonary disease or asthma; e.g. Biphenyl-2-ylcarbamic acid 1-(2-[5-(4-hydroxybenzylamino)pentylcarbamoyl]ethyl)piperidin-4-yl ester; long duration of action; reduced side effects, such as dry-mouth and constipation |
| 09/15/2005 | US20050203082 Administering with a carbamoylating agent such as BCNU [1,3-bis(2-chloroethyl)-1-nitrosourea] and CCNU [1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea]) to treat neoplastic disorders, such as glioblastoma multiforme; anticarcinogenic and antitumor agents; side effect reduction; brain cancer |
| 09/15/2005 | US20050203081 Inhibitors of protein tyrosine phosphatase 1B |
| 09/15/2005 | US20050203080 Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds |
| 09/15/2005 | US20050203079 Serotonin (5-HT) 2c receptors; antidepressants, anxiolytic agents; 3-(3,4-Dichloro-phenyl)-3-hydroxy-1-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrolidin-2-one for example |
| 09/15/2005 | US20050203076 E.g., 11-Dideoxy-4,11-dihydroxyiminorifamycin S and (R/S)-3-[4-(3-Carboxy-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinolin-7-yl)-2-methyl-piperazin-1-yl-aminomethylenyl]-11-deoxy-11-hydroxyiminorifamycin SV; especially effective against rifamycin-resistant microbes |
| 09/15/2005 | US20050203075 Antiangiogenic agents |
| 09/15/2005 | US20050203074 Modified aromatase inhibitors having improved bioavailability |
| 09/15/2005 | US20050203073 Method of treating inflammatory conditions with progesterone or progesterone analogs |
| 09/15/2005 | US20050203072 Administering a synergistic mixture of a substituted-pyrazole p38-kinase inhibitor, and an aldosterone antagonist or a diuretic; hypotensitve agents; congestive heart failure; antiarrhythmia, anticoagulant, and antiischemic, and antiinflammatory agents; urogenital, kidney, and brain disorders |
| 09/15/2005 | US20050203071 Use of carbon-2-modified-19-nor-vitamin d analogs to induce the formation of new bone |
| 09/15/2005 | US20050203070 Method of improving beta-adrenergic receptor function |
| 09/15/2005 | US20050203069 Nitric oxide-releasing molecules |
| 09/15/2005 | US20050203068 Pharmaceutical compositions containing water-soluble prodrugs of propofol and methods of administering same |
| 09/15/2005 | US20050203066 Preventing mitochondrial respiratory chain dysfunction in mammal by administering a pyrimidine nucleotide precursor and pyruvic acid, ester or salt; neurodegenerative, muscular, urogenital, or developmental disorders; autism, neuropathic pain, headaches; anticarcinogenic agents; cognition activators |
| 09/15/2005 | US20050203065 Use of A2b adenosine receptor antagonists such as 3-[4-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[2.2.2]oct-1-yl]-propionic acid (BG 9928) |
| 09/15/2005 | US20050203063 Proteasome pathway inhibitors and related methods |
| 09/15/2005 | US20050203062 Use of tagatose in laxatives |
| 09/15/2005 | US20050203060 Methods of using thalidomide in combination with irinotecan |
| 09/15/2005 | US20050203059 Methods and compositions for treatment of ischemia |
| 09/15/2005 | US20050203057 Treatment of cancers |
| 09/15/2005 | US20050203056 Chemoselectively O-sulfated compound of reduced hyaluronic acid as a single compound or as a mixture, or salts thereof; for treating or preventing disorders which display an increased activity of at least one of the matrix metalloproteinases; osteoarthritis |
| 09/15/2005 | US20050203055 Administering an effective amount of a sulfated polysaccharide for therapy and prophylaxis of fungal infection |
| 09/15/2005 | US20050203054 Use of lipid conjugates in the treatment of diseases |
| 09/15/2005 | US20050203053 Administering choline cytidine 5-pyrophosphate which raises levels of uridine or uridine phosphate; improving memory, learning, cognition, synaptic transmission, synthesis/release of neurotransmitters, and increasing brain phospholipid levels; Alzheimer's disease |
| 09/15/2005 | US20050203052 Antiinflammatory agents; antiarthritic agents; inflammatory resporatory disorders; antidiabetic agents |
| 09/15/2005 | US20050203051 Method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis |
| 09/15/2005 | US20050203045 Antisense modulation of cellular inhibitor of Apoptosis-2 expression |
| 09/15/2005 | US20050203035 Polymorphic forms of 6-11 bicyclic ketolide derivatives |
| 09/15/2005 | US20050203034 Multi-action anthelmintic formulations |
| 09/15/2005 | US20050203033 Identification and characterization of an anthocyanin mutant (ant1) in tomato |
| 09/15/2005 | US20050203032 Mannose phosphate and salts, for increasing vaginal cell growth in a mammal |
| 09/15/2005 | US20050203031 Useful for the treatment of type 2 diabetes, impaired glucose tolerance and certain other conditions |
| 09/15/2005 | US20050203030 Novel effectors of dipeptidyl peptidase IV |
| 09/15/2005 | US20050203029 Agents for treating <I>flaviviridae</I>infections |
| 09/15/2005 | US20050203027 Reduced toxicity, improved specificity for targeted protease |
| 09/15/2005 | US20050203019 Pharmacoperones for correcting disease states involving protein misfolding |
| 09/15/2005 | US20050203017 For activating the non-proteolytically activated thrombin receptor |
| 09/15/2005 | US20050203008 Compositions comprising pulmonary surfactants and a polymyxin having improved surface properties |
| 09/15/2005 | US20050203000 Use of benzyl alcohol, and other phenolic preservatives to reduce pain during intradermal injection |
| 09/15/2005 | US20050202983 Mono, di, oligo or polysaccharide solutions useful in the manufacture of gentle ophthalmic products that prevent tissue irritation; for topical application; solution, suspension, gel or ointment; contact lens care solution containing above carbohydrates |
| 09/15/2005 | US20050202681 Method and/or system for forming a thin film |
| 09/15/2005 | US20050202553 Animal cells and processes for the replication of influenza viruses |
| 09/15/2005 | US20050202549 Phosphodiesterase crystal for identifying modulators for use in treatment and prevention of sexual, pain and psychological disorders; drug screening and design |
| 09/15/2005 | US20050202540 Methods of producing hyaluronic acid using a recombinant hyaluronan synthase gene |
| 09/15/2005 | US20050202527 Fusion polypeptide comprising fibrinopeptide A, serine protease and thrombin-cleavable sequences for use in identifying modulators for prevention and treatment of thrombotic disorders; anticoagulants |
| 09/15/2005 | US20050202483 ITPase gene polymorphisms associated with adverse durg reactions to azathioprine therapy |
| 09/15/2005 | US20050202423 Identifying ribonucleic acid binding agents for use in prevention and treatment of human and/or feline immunodeficiency syndrome |
| 09/15/2005 | US20050202394 Organ arrest, protection, preservation and recovery |
| 09/15/2005 | US20050202148 Preparation of microbial oil |
| 09/15/2005 | US20050202110 Composition comprising an aqueous extract of red vine leaves and a blood circulation-improving agent |
| 09/15/2005 | US20050202107 Use of ginkgo biloba extracts in order to promote muscle mass to the detriment of fatty mass |
| 09/15/2005 | US20050202103 For treatment of obesity, reduction of blood glucose and blood pressure; sexual disorders |
| 09/15/2005 | US20050202101 Method and composition for preventing or reducing the symptoms of insulin resistance syndrome |
| 09/15/2005 | US20050202094 Nanosuspensions of anti-retroviral agents for increased central nervous system delivery |
| 09/15/2005 | US20050202089 Sustained-release pharmaceutical formulations containing mizolastine |
| 09/15/2005 | US20050202088 Pharmaceutical composition having a delayed active substance release, and method for the preparation thereof |
| 09/15/2005 | US20050202087 Combining alpha -dihydroergocryptine with a p hydrophilic swelling agent of hydroxyalkylcelluloses, polyvinyl alcohols, polyoxyethylene glycols, carbomers, poloxamers and excipients; improving bioavailability |
| 09/15/2005 | US20050202086 Lactose monohydrate, copovidon, hypromellose, and lubricant of magnesium stearate or anhydrous colloidal silica |
| 09/15/2005 | US20050202085 Enclosing a unit dose of aspirin in an enclosure having indications and a twist off cap, and a nutritional supplement of calcium |
| 09/15/2005 | US20050202083 Storage stable tablets of fosinopril sodium |
| 09/15/2005 | US20050202081 Stable pharmaceutical compositions comprising ace inhibitor(s) |
| 09/15/2005 | US20050202080 Mixing the salt or free base of the active pharmaceutical ingredient, tannic acid, and an anti-clumping agent to form a powder tannate salt complex; adding a liquid to the powder mixture to form a moistened blend; forming tablet, capsule or other solid dosage forms |
| 09/15/2005 | US20050202079 Nitrofurantoin monohydrate, sodium alginate, alginic acid and hypromellose in controlled release form; macrocrystalline nitrofurantoin in immediate release form; bacterial infection |
| 09/15/2005 | US20050202078 Long-circulating microvesicles with steroid hormones; microvesicles have an interaction with macrophages in the tumor, cell type could be down-regulated in tumor therapy, liberating the encapsulated corticosteroids to allow interaction with other cell types in and around the tumor |
| 09/15/2005 | US20050202076 Stabilization, homogenizing, sterile filtration, dehydration, reconstitution, ultrafiltration; storage stability; taxanes |
| 09/15/2005 | US20050202074 Method of administering liposomal encapsulated taxane |
| 09/15/2005 | US20050202066 Citric acid and a quaternary ammonium compound, an oxidizing agent of a halogen compound |
| 09/15/2005 | US20050202064 Administering an uronic acid or uronic acid derivative, a saccharide; anticarcinogenic |
| 09/15/2005 | US20050202062 Alfalfa sprout powder based supplement |
| 09/15/2005 | US20050202061 Optimized dosing for drug coated stents |
| 09/15/2005 | US20050202055 Retinoid of 4-(2,4-bistrimethylsilyphenylcarboxamide)benzoic acid or 4-[(5, 6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl) carbamoyl]benzoic acid; non irritanting |
| 09/15/2005 | US20050202053 Taste masking complex of antihistamine and alginate |
| 09/15/2005 | US20050202050 Single tank process for preparing tannate liquid and semi-solid dosage forms |
| 09/15/2005 | US20050202019 Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis |
| 09/15/2005 | US20050202005 Uses of inhibitors for the activation of CXCR4 receptor by SDF-1 in treating rheumatoid arthritis |
| 09/15/2005 | US20050201987 Porous carrier of ceramics or glass and pyrrolidone on the carrier for composites and bonding to carrier |
| 09/15/2005 | US20050201986 Cell targeting compositions and methods of using the same |
| 09/15/2005 | US20050201976 Selective inhibitors of nuclear factor-kappaB activation and uses thereof |
| 09/15/2005 | US20050201974 Bioadhesive polymers with catechol functionality |
| 09/15/2005 | US20050201972 Hydrophilic comonomers of alkylene glycol, vinyl alcohols, vinylpyrrolidone, and/or acrylamide; hydrophobic comonoomer of lactic acid, glycolic acid, 6-hydroxycaproic acid, and/or dioxan-2-one substituted with tocopherol or cholesterol; stable micelles for delivery of anticarcinogenic agents |